As anticipated, Evaxion has received a delisting determination The determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with Nasdaq’s equity requirement Evaxion remain committed to ensuring compliance and maintain our Nasdaq listing COPENHAGEN, Denmark, November 13, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company... Read More

New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also showcase the successful design of a proprietary prefusion glycoprotein B (gB) antigen with ability to neutralize the virus Evaxion is advancing these new findings to develop a multi-component CMV vaccine candidate About 1 in 200 babies is born with congenital CMV infection and... Read More

COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Business highlights (since last quarterly update) Since the second quarter 2024 business update, we have continued to execute strongly on our strategy and plans with... Read More

COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM. Evaxion’s Executive Management will host a conference call and webcast the same day at 13:30... Read More

Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence This underscores the platform’s unique potential in selecting effective vaccine targets The ongoing generation of relevant clinical data... Read More

Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through iterative learning and the integration of advanced bioinformatics and machine learning techniques In the ongoing phase 2 trial with personalized cancer vaccine EVX-01, 79% of the AI- Immunology™ predicted vaccine targets... Read More

Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3 Evaxion will host a conference call and webcast to discuss the agreement on September 27, 2024 COPENHAGEN, Denmark, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced... Read More

The new version 5.0 of the AI model EDEN ™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction feature The launch will expectedly improve Evaxion’s ability to fast and effectively discover AI-derived novel vaccines and is expected to further solidify the strong interest seen in AI-Immunology™ from potential partners New data demonstrating the improved... Read More

11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16 patients had a reduction of their tumors (target lesions) 79% of EVX-01’s vaccine targets triggered a targeted immune response, which compares very favorably to what is seen with other approaches A positive correlation was observed between the AI-Immunology™ platform predictions and neoantigen immune response... Read More

Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16 patients had reduction of their tumors (target lesions) The complete one-year dataset will be presented at the ESMO congress this week and discussed at a webinar with key opinion leader Professor Georgina V. Long on September 18,... Read More

New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteria The data confirm that Evaxion’s AI-Immunology™ platform is delivery modality agnostic COPENHAGEN, Denmark, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company... Read More

COPENHAGEN, Denmark, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2024 financial results. Business Highlights Since Last Quarterly Update Since the Q1 2024 financial results were released, we have continued to make progress on our three-pronged... Read More

COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion’s Executive Management will host a conference call and... Read More

COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is proud to announce the presentation of one-year clinical efficacy Phase 2 data for its lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain, from September 13-17,... Read More

Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and proprietary data, Evaxion has improved the performance of EvaxMHC compared to publicly available tools Precision in Vaccine Target Prediction: These advancements in... Read More

COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders. Dear Fellow Shareholders of Evaxion, The first half of 2024 has been off to a very productive start to the year for Evaxion. We have launched our refined strategy,... Read More

Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all relevant claims in the application, distinguishing the invention in the field of personalized cancer vaccines Strengthened Position: The... Read More

A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s personalized cancer vaccine, EVX-01, in patients with metastatic melanoma The findings also demonstrate strong and clinically relevant immune responses after EVX-01 administration to metastatic melanoma patients co-treated with anti-PD-1 standard of care The clinical study results substantiate the... Read More

Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patients Findings further confirm and validate the precision and predictive power of Evaxion’s AI vaccine target discovery and design platform, AI-Immunology™ COPENHAGEN, Denmark, June 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A /S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage... Read More

COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2024 financial results. Business Highlights Since Last Quarterly Update Since the 2023 full year financial results were released, the Company has continued to make... Read More

EVX-01 induced positive clinically relevant immune responses in all assessed patients Booster immunizations tended to increase the immune response The observed immune responses were mediated by both CD4+ and CD8+ T-cells COPENHAGEN, Denmark, May 23, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered... Read More

COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on May 7, 2024, it received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that it is not currently in compliance with... Read More

Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing Favorable safety profile confirmed Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces... Read More

Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infections The vaccine antigens significantly protected large, non-rodent animals against surgical site infections, indicating promising potential for clinical efficacy in human trials COPENHAGEN, Denmark, April 02, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A / S (NASDAQ:... Read More

Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines. Successful completion of initial phases of vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). MSD revealed as pharma... Read More

The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologies AI-Immunology™ outcompetes standard vaccine target discovery approaches and holds the promise of addressing serious unmet needs With a unique modular architecture, AI-Immunology™ is scalable and adaptable towards partner needs The potential of... Read More

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST. The R&D Day will feature a... Read More

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique... Read More

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with... Read More

COPENHAGEN, Denmark, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing on February 5, 2024 of its previously announced public offering of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase... Read More

COPENHAGEN, Denmark, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a... Read More

Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine solutions becomes feasible and highly promising for patients in need Transformative Vaccine Concept: This AI-Immunology™ powered vaccine concept offers the potential to provide treatment solutions to cancer patients who are usually unresponsive to cancer immunotherapy... Read More

COPENHAGEN, Denmark, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company’s previously disclosed change to its ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective. The... Read More

COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), from the current one (1) ADS representing one (1) ordinary... Read More

MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board of directors with significant participation in the total offering COPENHAGEN, Denmark, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company... Read More

Christian Kanstrup joined Evaxion as Chief Executive Officer in September Evaxion has launched its refined strategy with an increased focus on value realization via partnerships based upon the AI-Immunology™ platform Solid progress has already been seen on the refined strategy with two partnerships announced in Q3 and proof-of-principle for Evaxion’s proprietary responder model based upon the AI-Immunology™ platform Cash and... Read More

MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board of directors with significant participation in the total offering COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company... Read More

Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigens Broad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:... Read More

Evaxion today presents a novel AI model designed to predict patient responses to standard-of-care cancer immunotherapy The model demonstrates promising potential for improving patient outcomes, reducing healthcare costs and is scalable for broader applications Evaxion will pursue a partnership-based approach towards a commercial offering COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:... Read More

EVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 results Principal investigator Professor Adnan Khattak will walk us through this study’s encouraging results and explain its potential for revolutionizing cancer treatment COPENHAGEN, Denmark, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX)... Read More

Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive disease COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology ™... Read More

Data from Evaxion’s two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC) These new sets of clinical data further strengthen Evaxion’s position as a pioneering cancer vaccine company COPENHAGEN, Denmark, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company... Read More

COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that the Company received a letter (the “Notification Letter”) on September 29, 2023 from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that,... Read More

Partnership based on a highly protective vaccine candidate identified by Evaxion’s EDEN™ platform The collaboration will access mRNA technology from the WHO and Medicines Patent Pool’s mRNA Vaccine Technology Transfer Hub Afrigen responsible for the development and commercialization of the resulting mRNA vaccine in LMICs and African territories COPENHAGEN, Denmark, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S... Read More

AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary AI-platforms EDEN™ and RAVEN™ will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular immune response to the pathogen Collaborative and co-funded project between two companies with strong scientific alignment... Read More

Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine development Evaxion's AI model predicts vaccine efficacy in infectious disease models These results mean using EDEN TM will allow for a faster, cheaper, and lower-risk vaccine development compared to current approaches COPENHAGEN, Denmark, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the... Read More

COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced: Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s... Read More

Promising clinical data from Phase 1 and 2a studies with EVX-01 and EVX-02 were presented at AACR and ASCO in Q2 2023 A novel proprietary genetic vaccine adjuvant was presented at Evaxion’s R&D Day in May. The technology is an integral part of the next-generation cancer vaccine, EVX-03, planned for phase 1 clinical trial application in Q4 2023* Promising results on EVX-B1, a Staphylococcus aureus vaccine candidate, were... Read More

Financing, available in multiple tranches over the next three years, could extend the Company’s runway into Q4 2024 Transaction will enable Evaxion to advance its next-generation cancer vaccine, EVX-03, towards a Phase 1 clinical trial Copenhagen, DENMARK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development... Read More

EVX-B1, a vaccine against Staphylococcus aureus (S. aureus) containing AI-identified antigens, is highly protective against S. aureus disease in preclinical animal models EVX-B1 immunization resulted in complete bacterial clearance of S. aureus in multiple organs COPENHAGEN, Denmark, July 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company... Read More

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical responses were reported in 8 out of 12 EVX-01 treated patients High-quality neoantigens, predicted by AI technology, were associated with longer progression-free survival Strong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients Higher EVX-01 dose induced a stronger... Read More

Full read-out of the Phase 1/2a trial of EVX-02 in 10 patients with completely resected melanoma was presented at AACR in April 2023, meeting primary endpoints and demonstrating relapse-free survival in all EVX-02 completers Recent R&D Day highlighted Evaxion´s proprietary genetic adjuvant technology enhancing efficacy of DNA and mRNA vaccines Announcement of novel AI-platform for identification of a new source of... Read More

Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met primary endpoints for tolerability and safety COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, to present promising... Read More

Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccines Preclinically validated for both DNA and mRNA vaccines, and ready for clinical testing Anticipated large market potential for DNA and mRNA vaccines against cancer, viral and bacterial diseases COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the... Read More

COPENHAGEN, Denmark, May 16, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, today announced that it will hold an R&D Day at 12:30 p.m CEST on May 25, 2023. The R&D Day will feature a series of talks from Evaxion scientists and collaborators, sharing previously... Read More

Evaxion presented promising data from its Phase 1/2a clinical trial of EVX-02 in patients with late-stage melanoma at the 2023 AACR meeting EVX-03, a DNA-based personalized cancer vaccine, is expected to have a CTA filing in Q3 2023 and start a Phase 1 trial in solid tumor patients in Q4 2023 Recent collaborations with Pantherna Therapeutics GmbH (utilizing PIONEER™) and ExpreS 2 ion Biotechnologies ApS (utilizing RAVEN™)... Read More

All 10 patients with late stage melanoma who completed EVX-02 treatment demonstrated robust and treatment-specific immune responses and were relapse-free at their last assessment Results further validate predictive potential of proprietary AI technology and pave the way for advancement of EVX-03, a next-generation DNA-based personalized cancer immunotherapy, into the clinic in Q4 COPENHAGEN, Denmark, April 18, 2023 (GLOBE... Read More

COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful publication in Frontiers of Immunology of preclinical data demonstrating the effectiveness of its proprietary AI-driven viral vaccine discovery platform. The presented preclinical study was conducted in collaboration with... Read More

New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023 Phase 2b clinical trial reduced in size and expected to reach interim data on time (Q4 2023) Increased focus extends cash runway significantly COPENHAGEN, Denmark, March 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company... Read More

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy COPENHAGEN, Denmark, March 23, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered... Read More

COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting ( 2023 AACR ), taking place... Read More

COPENHAGEN, Denmark and HENNIGSDORF, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies and Pantherna Therapeutics GmbH (“Pantherna”), a biopharmaceutical company developing advanced nanoparticle solutions for the delivery and expression of mRNA therapeutics, today... Read More

COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for the Company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA ® . In December 2023,... Read More

COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01. In November 2022, the Company submitted an... Read More

COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023. By mid-2023, Evaxion... Read More